X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs IPCA LABS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA IPCA LABS GSK PHARMA/
IPCA LABS
 
P/E (TTM) x 55.9 37.2 150.0% View Chart
P/BV x 10.0 3.4 291.3% View Chart
Dividend Yield % 1.3 0.1 845.6%  

Financials

 GSK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
IPCA LABS
Mar-17
GSK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,838643 596.9%   
Low Rs2,637503 524.5%   
Sales per share (Unadj.) Rs354.2254.4 139.2%  
Earnings per share (Unadj.) Rs39.816.1 247.4%  
Cash flow per share (Unadj.) Rs42.929.8 144.0%  
Dividends per share (Unadj.) Rs30.001.00 3,000.0%  
Dividend yield (eoy) %0.90.2 530.9%  
Book value per share (Unadj.) Rs236.9194.6 121.8%  
Shares outstanding (eoy) m84.70126.20 67.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.12.3 405.9%   
Avg P/E ratio x81.435.7 228.4%  
P/CF ratio (eoy) x75.519.2 392.5%  
Price / Book Value ratio x13.72.9 464.0%  
Dividend payout %75.46.2 1,212.4%   
Avg Mkt Cap Rs m274,21672,300 379.3%   
No. of employees `0004.713.3 35.3%   
Total wages/salary Rs m4,8306,960 69.4%   
Avg. sales/employee Rs Th6,387.02,413.5 264.6%   
Avg. wages/employee Rs Th1,028.3523.2 196.6%   
Avg. net profit/employee Rs Th717.1152.4 470.4%   
INCOME DATA
Net Sales Rs m30,00032,106 93.4%  
Other income Rs m728226 322.6%   
Total revenues Rs m30,72832,332 95.0%   
Gross profit Rs m4,1904,448 94.2%  
Depreciation Rs m2631,730 15.2%   
Interest Rs m0241 0.0%   
Profit before tax Rs m4,6552,703 172.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744675 258.3%   
Profit after tax Rs m3,3682,028 166.1%  
Gross profit margin %14.013.9 100.8%  
Effective tax rate %37.525.0 150.0%   
Net profit margin %11.26.3 177.7%  
BALANCE SHEET DATA
Current assets Rs m16,74217,340 96.6%   
Current liabilities Rs m7,2029,559 75.3%   
Net working cap to sales %31.824.2 131.2%  
Current ratio x2.31.8 128.2%  
Inventory Days Days52100 51.7%  
Debtors Days Days2157 36.5%  
Net fixed assets Rs m8,63520,779 41.6%   
Share capital Rs m847252 335.6%   
"Free" reserves Rs m19,22224,499 78.5%   
Net worth Rs m20,06924,553 81.7%   
Long term debt Rs m103,517 0.3%   
Total assets Rs m30,03839,595 75.9%  
Interest coverage xNM12.2-  
Debt to equity ratio x00.1 0.3%  
Sales to assets ratio x1.00.8 123.2%   
Return on assets %11.25.7 195.7%  
Return on equity %16.88.3 203.2%  
Return on capital %25.510.5 242.8%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m52815,617 3.4%   
Fx outflow Rs m7,1935,828 123.4%   
Net fx Rs m-6,6659,790 -68.1%   
CASH FLOW
From Operations Rs m2,3602,764 85.4%  
From Investments Rs m3,008-1,432 -210.1%  
From Financial Activity Rs m-5,108-1,591 321.0%  
Net Cashflow Rs m260-259 -100.6%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.4 89.5%  
FIIs % 23.8 25.3 94.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   102,036 36,892 276.6%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


May 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS